Showing 1 - 20 results of 2,562 for search '(( free ((step decrease) OR (small decrease)) ) OR ( i ((larger decrease) OR (marked decrease)) ))', query time: 0.58s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    S1 File - by Hongyu Li (1332669)

    Published 2025
    “…Following the overexpression of miRNA 221 in myocardium, there was a marked alleviation of myocardial injury and cardiomyocyte apoptosis and necrosis, significant enhancement of left ventricular systolic function, and marked decrease in the levels of PLB, p-PLB (Ser16), p-PLB (Thr17), caspase 3 and Cyt C, as well as a significant decrease in total calcium levels in myocardium.…”
  9. 9
  10. 10
  11. 11

    Biases in larger populations. by Sander W. Keemink (21253563)

    Published 2025
    “…Threshold parameter <i>c</i> = − 0 . 1 for the rectified cosine tuning with 4 neurons, and width <i>w</i> was 1 for von Mises tuning. …”
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Experimental assessment of the effects of substrate choice on the duration of chemical signals in fecal scent-marks of free-ranging Iberian wolves by Elisa Espartosa (16991340)

    Published 2025
    “…<p dir="ltr">Chemical communication, typically based on feces, urine and glandular secretions, plays a key role in social organization and communication among many mammals, especially carnivores. Scent marking is crucial for diverse functions. This study assesses experimentally whether the type of substrate chosen for fecal deposition and the temperature reached by these substrates influence the persistence of volatile compounds in feces of the Iberian wolf (<i>Canis lupus signatus</i>), considering their role in chemical communication. …”
  17. 17
  18. 18
  19. 19
  20. 20

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”